Navigation Links
Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials

SPIRIT FIRST Demonstrates Continued Safety for XIENCE V with No Late Stent Thrombosis or Additional Major Adverse Cardiac Events Out to Three Years

BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Three-year data from the SPIRIT FIRST trial demonstrated no additional Major Adverse Cardiac Events (MACE), and no late stent thrombosis in patients treated with either Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent System or its MULTI-LINK VISION(R) metallic coronary stent. Additionally, data presented from a meta- (combined) analysis of SPIRIT II and SPIRIT III trials at nine months reaffirmed the superiority of Abbott's XIENCE V compared to the TAXUS(R) paclitaxel-eluting coronary stent system in a variety of measures.

These data were presented today at the EuroPCR meeting in Barcelona.

"The SPIRIT FIRST results support the long-term safety of the XIENCE V system, with no additional MACE or late stent thrombosis, by both protocol and ARC definitions, out to three years," said Gregg W. Stone, M.D., of Medical Center and the Cardiovascular Research Foundation, New York, and an investigator in the SPIRIT trials. "In addition, a meta-analysis of the SPIRIT II and III data again demonstrated the superiority of the XIENCE V system to the TAXUS system in important measures that matter to patients including renarrowing of a treated vessel and major adverse cardiac events."

A meta-analysis of approximately 1,300 patients from the SPIRIT II and SPIRIT III clinical trials conducted by the Cardiovascular Research Foundation indicated that the XIENCE V system demonstrated superiority over the TAXUS stent in angiographic (imaging) and clinical endpoints, with an excellent safety profile.

Specifically, data from the meta-analysis demonstrated that the XIENCE V Everolimus Eluting Coronary Stent System was superior to the TAXUS stent in:

    -- Reducing the occurrence of major 
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Nov. 29, 2016 Several leading ... by Accera, Inc. at 11 a.m. EST ... International Conference on Clinical Trials for Alzheimer,s Disease (CTAD). ... metabolism in Alzheimer,s disease and therapeutic targets that address ... "Following the recent failure of another therapy targeting ...
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... Blotting Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, ... Companies) - Global Forecasts to 2021" report to their offering. ... , , ... reach USD 730.7 Million in 2021 from USD 574.8 Million in ...
(Date:12/5/2016)... and PUNE, India , December 5, 2016 /PRNewswire/ ... titled, "Surgical Sutures Market by Product Type and by Application - Global Opportunity ... for $3,360 million in 2015, and is expected to reach $5,255 million by ... segment dominated the market in 2015 with more than four-fifths share. ... ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 2016 , ... Just in time for the holiday season, the celebrated paleo ... for Honeyville’s new Organic Quinoa Flour product for sale at Costco stores throughout the ... , “I think it’s wonderful that a growing number of retailers such as ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement ... of the world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... of a powerful woman's story of sacrifice and enlightenment. , “Tatiana ... author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing through ...
(Date:12/6/2016)... ... December 06, 2016 , ... The OSHA Training Center ... Education Center headquartered in Northern California, has announced the addition of a Public ... health training to public sector employees. , “The primary goal of the Public ...
(Date:12/5/2016)... ... 05, 2016 , ... What: Shriners Hospitals for Children, with the help of ... – using a video monitor and web-enabled camera. Santa visits with children through Dimension ... a Christmas Wonderland, which is where the video connection to the North Pole will ...
Breaking Medicine News(10 mins):